RUN for RUN DIPG: Dr Matt Dun has hope new clinical trial will further research into rare DMG/DIPG childhood brain cancer

Updated September 23 2021 - 8:56pm, first published 7:00pm
RESEARCH: Hunter biomedical scientist Dr Matt Dun has been researching new treatments for an aggresive and rare paediatric brain cancer. A new clinical trial is expected to open in October. Picture: Simone De Peak
RESEARCH: Hunter biomedical scientist Dr Matt Dun has been researching new treatments for an aggresive and rare paediatric brain cancer. A new clinical trial is expected to open in October. Picture: Simone De Peak

An international clinical trial to test a combination of anticancer drugs for the treatment of the most aggressive form of children's cancer, diffuse midline glioma (DMG) otherwise known as diffuse intrinsic pontine glioma (DIPG) is only months away from Australian hospitals, based on ongoing research conducted by the Hunter Medical Research Institute and University of Newcastle.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Newcastle news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.